Company / Accounts Receivable
Lexaria Bioscience Corp. Accounts Receivable History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$368.4K
FY2025
5-year range
$154.5K / $368.4K
FY2021-FY2025
Trend
+138.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable returned to growth in FY2025 after 3 years of decline, reaching $368,358.
Based on SEC 10-K filings.
$368,358 in FY2025 with a 10-year CAGR of +27.9%.
Improved from $175,245 to $368,358 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +22.2%
- 5-Year CAGR
- +3.2%
- 10-Year CAGR
- +27.9%
Key checks
Key Insights
- 5-year CAGR of +3.2%, indicating consistent growth.
- In FY2025, accounts receivable increased 138.5% year-over-year.
- Lowest accounts receivable in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $368.4K | +138.5% |
| FY2024 | $154.5K | -11.9% |
| FY2023 | $175.2K | -13.2% |
| FY2022 | $201.8K | -41.1% |
| FY2021 | $342.4K | +9.1% |
| FY2020 | $313.9K | +14.9% |
| FY2019 | $273.1K | +503.1% |
| FY2017 | $45.3K | -65.4% |
| FY2016 | $131.1K | +317.7% |
| FY2015 | $31.4K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026